COLUMBUS, Ohio, July 23 (Nationwide Times) — A specially made tomato-soy drink lowered three inflammation-related proteins in adults with obesity in a small Ohio State University study. The result is interesting, but it does not mean ordinary tomato juice is a proven treatment or that people should change their diet based on this one trial.
What did the researchers test?
According to the study published in Molecular Nutrition & Food Research, 12 adults with obesity drank two 6-ounce servings a day for four weeks. One drink was a specially formulated tomato-soy beverage made from tomatoes bred to contain high levels of lycopene and fortified with soy isoflavones. The comparison drink was a low-carotenoid tomato juice.
The study used a crossover design, which means participants went through both drinks, with a washout period in between. That kind of setup lets researchers compare results within the same group of people.
What changed in the body?
The study measured cytokines, which are immune-system messenger proteins tied to inflammation. After the tomato-soy drink, the researchers reported significant drops in three of them: IL-5, IL-12p70, and GM-CSF.
Another marker, TNF-α, also moved downward, but it did not meet the usual statistical cutoff for significance. In plain terms, the change looked promising, but it was not strong enough in this small study to count as a clear finding.
The study also found that plasma lycopene rose 2.48-fold after the tomato-soy drink. Lycopene is a plant pigment found in tomatoes.
Researchers also reported changes in the urine metabolome, which is a snapshot of small molecules the body makes and breaks down. The study said some of those changes appeared in both drink groups, suggesting that tomatoes themselves may affect the body in ways that are not fully explained by lycopene alone.
How should readers interpret this?
The main takeaway is narrow: a specially designed tomato-soy drink showed a signal that it may affect inflammation markers in adults with obesity. But the study was very small, lasted only four weeks, and looked at lab markers rather than long-term health outcomes.
That means the research does not show whether the drink lowers disease risk, improves symptoms, or replaces other care. It also does not prove that regular tomato juice would do the same thing, because the study drink was not ordinary juice. It was made with tomatoes bred for more lycopene and was fortified with soy isoflavones.
Has tomato juice been studied before?
Yes. A separate 2013 study listed in PubMed looked at tomato juice in overweight and obese female students at Tehran University of Medical Sciences. That study reported reductions in some inflammatory markers, including IL-8 and TNF-α in the intervention group, and IL-6 in obese subjects.
Because that earlier trial involved a different group of people and a different design, it should be seen as background rather than a direct comparison with the Ohio State study.
For now, the evidence suggests promise, not proof. The study adds to early research on how tomato compounds may interact with inflammation, but it is too small to support broad health claims.
